Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
M. Faehling
J. Achenbach
P. Staib
U. Steffen
H. W. Tessen
V. E. Gaillard
W. Brugger
机构：
[1] Esslingen Hospital,Clinic for Cardiology und Pneumology
[2] Lung Clinic Lostau,Department of Pulmonary Diseases and Thoracic Oncology
[3] St. Antonius Hospital,Clinic for Hematology and Oncology
[4] Pneumonology,Hematology/Oncology, Schwarzwald Baar Clinic, Acad. Teaching Hospital
[5] Private Practice,undefined
[6] Oncology/Hematology,undefined
[7] Oncological Cooperation Harz,undefined
[8] Roche Pharma AG,undefined
[9] Medical Affairs,undefined
[10] University of Freiburg,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2018年 / 144卷
关键词：
Non-small cell lung cancer; Erlotinib maintenance therapy; Non-interventional study; EGFR; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1375 / 1383
页数：8
相关论文
共 50 条
  • [1] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Brugger, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Gaillard, V. E.
    Brugger, W.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1375 - 1383
  • [3] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [4] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [5] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
    Coudert, B.
    Ciuleanu, T.
    Park, K.
    Wu, Y. -L.
    Giaccone, G.
    Brugger, W.
    Gopalakrishna, P.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2012, 23 (02) : 388 - 394
  • [6] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [7] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
    Merimsky, Ofer
    Cheng, Chi-Kin
    Au, Joseph Siu-Kie
    Von Pawel, Joachim
    Reck, Martin
    ONCOLOGY REPORTS, 2012, 28 (02) : 721 - 727
  • [8] ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chung, Carmen
    Jiang, Haiyan
    Isaranuwatchai, Wanrudee
    Di Maio, Mas-Simo
    Lau, Anthea
    Hoch, Jeffrey
    Feld, Ronald
    Tsao, Ming-Sound
    Gridelli, Cesare
    Gallo, Ciro
    Ciardiello, Fortunato
    Butts, Charles A.
    Perrone, Francesco
    Leighl, Natasha B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S602 - S603
  • [9] Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).
    Chung, Carmen
    Isaranuwatchai, Wanrudee
    Di Maio, Massimo
    Jiang, Haiyan
    Lau, Anthea
    Hoch, Jeffrey S.
    Feld, Ronald
    Tsao, Ming Sound
    Gridelli, Cesare
    Ciardiello, Fortunato
    Butts, Charles Andrew
    Gallo, Ciro
    Perrone, Francesco
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
12345